Patents by Inventor Jeremy Schulenburg York

Jeremy Schulenburg York has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Piperidinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
    Patent number: 7829582
    Abstract: The present invention discloses novel compounds of Formula I: having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: November 9, 2010
    Assignee: Eli Lilly and Company
    Inventors: Owen Brendan Wallace, Yanping Xu, Jeremy Schulenburg York
  • Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
    Patent number: 7816349
    Abstract: The present invention discloses novel compounds of Formula I: (I) possessing 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11?-HSD type 1 activity.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: October 19, 2010
    Assignee: Eli Lilly and Company
    Inventors: John Gordon Allen, Alexei Pavlovych Krasutsky, Owen Brendan Wallace, Yanping Xu, Jeremy Schulenburg York
  • Phenoxyether derivatives as PPAR modulators
    Patent number: 7608639
    Abstract: The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR), such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: October 27, 2009
    Assignee: Eli Lilly and Company
    Inventors: Leonard Larry Winneroski, Jr., Yanping Xu, Jeremy Schulenburg York
  • CYCLOHEXYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1
    Publication number: 20090239911
    Abstract: The present invention discloses novel compounds of Formula I: having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Application
    Filed: April 24, 2007
    Publication date: September 24, 2009
    Inventors: Owen Brendan Wallace, Yanping Xu, Nancy June Snyder, Jeremy Schulenburg York, Alexei Pavlovych Krasutsky
  • BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1
    Publication number: 20090156571
    Abstract: The present invention discloses novel compounds of Formula I: possessing 11 ?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 ?-HSD type 1 activity.
    Type: Application
    Filed: April 19, 2007
    Publication date: June 18, 2009
    Inventors: Thomas Daniel Aicher, Zhaogen Chen, Ronald Jay Hinklin, Gary Alan Hite, Alexei Pavlovych Krasutsky, Renhua Li, Jefferson Ray McCowan, Ashraf Saeed, Nancy June Snyder, James Lee Toth, Owen Brendan Wallace, Leonard Larry Winneroski, Jr., Yanping Xu, Jeremy Schulenburg York
  • PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1
    Publication number: 20090088430
    Abstract: The present invention discloses novel compounds of Formula I: having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Application
    Filed: April 27, 2007
    Publication date: April 2, 2009
    Inventors: Owen Brendan Wallace, Yanping Xu, Jeremy Schulenburg York
  • SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1
    Publication number: 20090069326
    Abstract: The present invention discloses novel compounds of Formula I: (I) possessing 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11?-HSD type 1 activity.
    Type: Application
    Filed: April 23, 2007
    Publication date: March 12, 2009
    Inventors: John Gordon Allen, Alexei Pavlovych Krasutsky, Owen Brendan Wallace, Yanping Xu, Jeremy Schulenburg York
  • Pyrazolopyridine derivatives as pharmaceutical agents
    Patent number: 7365066
    Abstract: Novel pyrazolopyridine derivative compounds are disclosed and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF beta.
    Type: Grant
    Filed: September 16, 2003
    Date of Patent: April 29, 2008
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Rosanne Bonjouklian, Junkai Liao, William Thomas McMillen, Brandon Lee Parkhurst, Jason Scott Sawyer, Jonathan Michael Yingling, Jeremy Schulenburg York
  • Methods and compounds for inhibitting MRP1
    Publication number: 20040176405
    Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).
    Type: Application
    Filed: March 10, 2004
    Publication date: September 9, 2004
    Inventors: Julian Kroin, Bryan Hurst Norman, Jeremy Schulenburg York
  • Methods and compounds for inhibiting MRP1
    Patent number: 6743794
    Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: June 1, 2004
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Jeffrey Daniel Cohen, Joseph Michael Gruber, Douglas Webb Johnson, Louis Nickolaus Jungheim, Julian Stanley Kroin, Peter Ambrose Lander, Ho-Shen Lin, Mark Christopher Lohman, Brian Stephen Muehl, Bryan Hurst Norman, Vinod Francis Patel, Michael Enrico Richett, Kenneth Jeff Thrasher, Sreenivasarao Vepachedu, Wesley Todd White, Yongping Xie, Jeremy Schulenburg York, Brandon Lee Parkhurst, Qiupang Wang
  • Methods and compounds for inhibiting MRP1
    Patent number: 6686376
    Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: February 3, 2004
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Jeremy Schulenburg York
  • Methods and compounds for inhibiting mrp1
    Publication number: 20030100576
    Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).
    Type: Application
    Filed: May 21, 2002
    Publication date: May 29, 2003
    Inventors: Rosanne Bonjouklian, Jeffrey Daniel Cohen, Joseph Michael Gruber, Douglas Webb Johnson, Louis Nickolaus Jungheim, Julian Stanley Kroin, Peter Ambrose Lander, Ho-Shen Lin, Mark Christopher Lohman, Brian Stephen Muehl, Bryan Hurst Norman, Vinod Francis Patel, Michael Enrico Richett, Kenneth Jeff Thrasher, Sreenivasarao Vepachedu, Wesley Todd White, Yongping Xie, Jeremy Schulenburg York, Brandon Lee Parkhurst